



DISCLAIMER

This presentation is for discussion purposes only and does not constitute an offering in any way or any jurisdiction. Reproduction and communication of this document in any form or manner is strictly prohibited. This document has not been independently verified and the authors are not liable for any claims or obligations whatsoever that may be attributable to this document. This document is strictly private and confidential and remains the property of the authors.


All investors/partners should seek independent and competent advice on the suitability of this opportunity in meeting their investment/partnership needs before making a decision to invest/engage in this opportunity.

This presentation may contain forward-looking statements which reflect Simplicardiac's management views with respect to, among other things, Simplicardiac's operations and financial performance. These forward-looking statements are identified by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "seeks," "approximately," "predicts," "intends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Simplicardiac's management undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.




simplicardiac

**Automated vascular access
site management**




BACKGROUND- ACCESS SITES

Access site management is a key element of postprocedural **patient care**



ACCESS SITE MANAGEMENT AREA HAS NOT EXPERIENCED A GAME CHANGING INNOVATION SINCE INCEPTION AND IS POISED WITH 'ME TOO' DEVICES AND INCREMENTAL OPERATIONAL IMPROVEMENTS

CATHLAB WORK ORGANIZATION ENVIRONMENT



The worldwide paradigm has shifted towards the radial method and SDD emerges as a state of the art in postprocedural care. Simplicardiac is capitalizing on these trends and is proactively developing solutions that shape the way CathLabs will be organised in the future.

SIMPLICARDIAC'S INSIGHT

Available solutions and tools are not enough



CONSTANT INCREASE IN NUMBER OF PROCEDURES

30% increase in elective PCI procedures¹



Trans radial access dominance

more than 14 M radial compatible in developed countries²



No automated solutions for access site management

No remote patient monitoring

There is enormous untapped potential in cathlab digitalization and robotization. In our opinion the best way to tap into it is through a niche market of Arteriotomy Closure Devices.





SIMPLICARDIAC

Outcome driven approach



SMART CATHLAB SOLUTION

simpli**active**

bots & platform

SIMPLICARDIAC RADIAL PUNCTURE CLOSURE BOT

simpli**active** first-in-class solution for transradial approach



Truly significant innovation is when new technology leads to improved organization.”

Mariusz Kruk MD, PhD - inventor
Chief Medical Officer, Co-founder



MARKET NEEDS

- Medical personel shortage and work overload
- Postoperative complications (eg. radial artery occlusions) due to suboptimal wound care in standard clinical setting
- Suboptimal **time** to hemostasis (could be shortened)



INNOVATION

simpli**active**
bots & platform

CREATES A NOVEL CLASS

of medical devices
at the interface of
arteriotomy closure,
cathlab robotisation
& remote patient monitoring

capable to respond to all identified
market needs




EXISTING SOLUTIONS

**NO SOLUTIONS
ON THE MARKET**

SIMPLICARDIAC simpli**active bots** & platform **IDEA**

TODAY'S PASSIVE RADIAL BANDS



- Direct supervision
- More personnel needed


Simpli**active** bots & platform



- Remote supervision
- Less personnel needed

Simpli**active** bots & platform

Benefits of automated **radial** access site management




Immediate solution to important and growing unmet business need – significantly reduces workload of cathlab personnel

Viable potential to reduce wound closure related postoperative complications (eg. radial artery occlusions)

Viable potential to reduce time to hemostasis (building on SDD best practice)

Once established easily scalable and modular – susceptible to further vertical and horizontal (eg. femoral wound closure) expansion

Provides robust modality to gather large amounts of real-world cathlab data – paramount to building further Web 3.0 applications, including AI optimisation of postoperative care



simpli**radial**TM

**Radial Puncture Closure
Device**

simpliradial™ – PASSIVE ARTERIOTMY CLOSURE DEVICE

Intuitive, **globally unique** manual passive device for wound closure



MARKET NEED

- Better intuitiveness of the procedure



EXISTING SOLUTIONS










- Multi-component (eg. band + air jet pumping syringe)
- Inconvenient
- Difficult to operate – two-person / longer procedure



simpliradial™

- Single-component
- Precise/intuitive
- Out-of-the-box design

SIMPLICARDIAC'S ROADMAP TOWARDS information age post catheterisation patient care

	 Device innovation	 Robotization	 Digitalization
simpliradial™ Manual radial band <ul style="list-style-type: none">Worldwide uniqueEarly access 2024			
simpliactive bots Automated access site management device <ul style="list-style-type: none">First-in-classPrototype ready			
simpliactive platform <ul style="list-style-type: none">Remote Patient Monitoring system for automated access site managementConceptual stage			



SIMPLICARDIAC

Who we are

THE HEART OF SIMPLICARDIAC- MANAGEMENT

Comprehensive competences held in-house



Andrzej Białkowski-Miler

CEO, Co-founder

Biotech & MedTech entrepreneur and consultant with >16 years of experience in all stages of technology transfer and start-up development.

- Founder and CEO at BMC/Biotech Management Consulting (boutique consultancy providing technology due diligence and valuation services)
- EMBA candidate, **Chicago Booth**
- MS in Technology Commercialization **University of Texas/ Łódź**
- MS in Biotechnology (honors)



Prof. Mariusz Kruk MD

Chief Medical Officer, Co-founder

Inventor, serial innovator and patent holder. Scientist, clinician, operator, and investigator, specialising in the optimization of new medical procedures and diagnostic methods.

- >20 clinical trials within cardiology, invasive cardiology (role of PI)
- >140 publications
- Associate Professor at The National Institute of Cardiology
- MD, PhD Cardiologist, Invasive cardiologist




MARKET DATA & CHARACTERISTICS

**Cardiovascular Diseases
Interventional Cardiology**


INTERVENTIONAL CARDIOLOGY MARKET

Market growth due to the CVDs incidence and technological advances


US CATH LAB MARKET SIZE [bn USD]¹



GLOBAL INTERVENTIONAL CARDIOLOGY MARKET – GROWTH¹



GLOBAL INTERVENTIONAL CARDIOLOGY MARKET – MAIN SEGMENTS²



- The global interventional cardiology market comprises of >400 products from >100 companies
- **ACDs remain a niche, with relatively low competition and great potential for technological improvement**



SUMMARY



Innovation by Practice

Experienced experts dealing with hospital problems on a daily basis.



Strong Team

Highly experienced team, advisory committee and investors specialized in cardio and healthcare market.



Asset-light Model

Low infrastructure investments – core IP and competencies held in-house. Quality know-how and services sourced externally.



Towarzystwo Funduszy Inwestycyjnych S.A.